Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-1293|19|3|175-183

ISSN： 1464-2662

Source： HIV MEDICINE, Vol.19, Iss.3, 2018-03, pp. : 175-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

By  

HIV MEDICINE, Vol. 16, Iss. 5, 2015-05 ,pp. : 297-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake

By  

HIV MEDICINE, Vol. 16, Iss. 10, 2015-11 ,pp. : 599-607

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection

By  

HIV MEDICINE, Vol. 16, Iss. 6, 2015-07 ,pp. : 355-361

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current and Novel Inhibitors of HIV Protease

By Pokorná Jana   Machala Ladislav   Řezáčová Pavlína   Konvalinka Jan  

Viruses, Vol. 1, Iss. 3, 2009-12 ,pp. : 1209-1239

MDPI

Access to resources Recommend Favorite

Role of Gag in HIV Resistance to Protease Inhibitors

By Clavel François   Mammano Fabrizio  

Viruses, Vol. 2, Iss. 7, 2010-07 ,pp. : 1411-1426

MDPI

Access to resources Recommend Favorite